Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced it has secured $235 million through the successful close of its Series B preferred stock financing and a credit facility. The Company raised $85 million in Series B financing led by Janus Henderson, EQT Nexus, Hillhouse and British Business Bank. Existing investors also participating incl